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COX-2 inhibitors were marketed
aggressively and rapidly gained wide
popularity among prescribing physicians
based on the propagated belief that they
had a better ADR profile; especially with
regards to gastrointestinal side-effects when
compared to traditional NSAIDs.
Two independent studies, the VIGOR-
study (rofecoxib vs naproxen) and the
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Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most
widely prescribed groups of medicines in clinical practice, their anti-
inflammatory, analgesic and anti-pyretic properties making them
central to the management of osteoarthritis and rheumatoid
arthritis.  Gastro-intestinal toxicity represents some of the most-
serious adverse drug reactions of this class of drugs.  In an attempt
to minimize these side-effects, selective cyclo-oxygenase-2 (COX-2)
inhibitors were developed. In light of increasing concerns regarding
their safety, two COX-2 inhibitors – rofecoxib and valdecoxib were
withdrawn from the market in September 2004 and April 2005
respectively.  Various restrictions have been also imposed on all the
other selective COX-2 Inhibitors.
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CLASS-study (celecoxib vs ibuprofen or
diclofenac) concluded that the intake of
both rofecoxib and celecoxib was associated
with a decrease in upper gastrointestinal
toxicity when compared to other NSAIDs.12,13
Both studies were extensively criticized
regarding data analysis, publishing policy
and study design.14,15  From the beginning it
was obvious that at least rofecoxib was
associated with an increased risk of
cardiovascular events and that the
gastrointestinal benefits of COX-2 inhibitors
were at best marginal and completely lost if
the patient has to take aspirin.12,16,17 The
VIGOR trial in fact noted a five-fold higher
incidence of myocardial infarction in the
rofecoxib group compared with the
naproxen group.12,18 Naproxen inhibits the
production of thromboxane and platelet
aggregation, and the difference in
cardiovascular risk was attributed to a
cardioprotective effect of naproxen, rather
than a cardiotoxic effect of rofecoxib.12
This interpretation was reiterated in a 2001
meta-analysis of randomised trials of
rofecoxib and three case-control studies of
naproxen and myocardial infarction
published in 2002. 19-22
Regulatory action
The first global signal of a problem with
COX-2-selective inhibitors came in October
2000 – six months after the launch of
rofecoxib where evidence for high reporting
odds ratio for cardiovascular ADRs with
some fatalities and which occurred early in
treatment with rofecoxib were presented for
the first time at a WHO International Drug
Monitoring Programme meeting in Tunis.23,24
A cumulative meta-analysis of randomised
controlled trials in 2001 indicated that an
increased risk of myocardial infarction was
evident from 2000 onwards; at the end of
2000, the effect was both substantial and
unlikely to be a chance finding.25 Concerns
were shared with various regulatory
authorities who implemented various
labeling changes in 2002, which had as
expected no impact on the prescription
patterns of selective COX-2 inhibitors.
Data from a placebo-controlled trial
with rofecoxib (25mg daily) for the
prevention of adenomatous polyps
(APPROVe study) proved unequivocally in
September 2004 that (as indicated by
VIGOR) there was a significant increase in
the incidence of serious thromboembolic
adverse events for patients taking rofecoxib
for more than 18 months.26 The trial was
stopped and rofecoxib (available in Malta
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NSAIDs are a chemically diverse
group of agents (although most of them
are organic acids), that share similar
pharmacological properties and adverse-
drug-reactions.  They are widely-used for
the control of pain and inflammation but
prospective studies have shown a
significant risk of serious
gastrointestinal complications and
mortality associated with NSAID use.1-5
It is well known that both the
therapeutic and toxic effects of NSAIDs
are mediated by the inhibition of
cyclooxygenase (COX) (of which there are
three forms6,7) and consequent inhibition
of prostanoids (a term which
encompasses prostacyclins and
thromboxanes). Prostanoids are released
in the inflammatory process;
predominantly PGE
2
 but also PGI
2
; both
generated by local tissues and blood
vessels; and PGD
2
 released by mast cells.6
PGE
2
, PGI
2
 and PGD
2
 are powerful
vasodilators and synergise with other
inflammatory vasodilators such as
histamine and bradykinin to dilate
precapillary arterioles to contribute to
the increased blood flow characteristic of
acute inflammation.6  They also
potentiate the effect of bradykinin by
sensitising afferent C fibres and thus
produce pain.6 The anti-inflammatory
effects of NSAIDs thus result largely from
the prevention of these actions of
Overview of NSAID Pharmacology
prostaglandins.
Prostaglandins have also a gastro-
protective action.  PGE2 when acting on
EP3 receptors inhibits gastric acid
secretion and increses gastric mucus
secretion.  Through COX inhibition there is
also an inhibition of PGE2, which explains
why adverse gastrointestinal events are
the commonenst unwanted effects of
NSAIDs.6
There are three isoforms of COX; COX-
1, COX-2 and COX3 which has recently
been described.6,7,8 COX are bifunctional
having two distinct activities; the main
action which gives PGG
2
, and a peroxidase
action, which converts PGG
2
 to the
unstable PGH
2
 which is then converted
into another prostaglandin.6 According to
the working hypothesis that constitutive
COX-1 is responsible for the physiological
production of prostanoids and inducible
COX-2 for the elevated production of
prostanoids at sites of inflammation,
selective COX-2-inhibitors have been
developed in the hope of a specific anti-
inflammatory function and less
gastrointestinal side-effects attributable
to inhibition of COX-1. Most traditional
NSAIDs in current use are inhibitors of
both isoenzymes though they vary in their
degree of inhibition of each.9,10 Ketorolac,
flurbiprofen, suprofen, ketoprofen,
indomethacin, aspirin, naproxen, tolmetyn
and fenoprofen are COX-1 selective in
vitro.9,10  Zomepirac, niflumic acid, sodiun
salicylate, diflusinal,  piroxicam,
tomoxiprol, meclofenamate, sulindac and
diclofenac have a less than five-fold
selectivity to COX-2.9,10  Nimesulide,
celecoxib, meloxicam and etodolac have a
five to fifty fold selectivity towards COX-2,
whilst still producing full inhibition of
COX-1.  Rofecoxib has a greater than 50-
fold selectivity towards COX-2.9,10
Both COX-1 and COX-2 are
predominantly located on the lumenal side
of the endoplasmic reticulum membrane
and the nuclear membrane and each
consists of a long, largely hydrophobic,
channel with a bend at the end, the
channel being wider in COX-2.11
Arachidonic acid enters and has two
oxygens inserted and a free radical
extracted, resulting in the 5-carbon ring
characteristic of the prostaglandins.   The
crucial structural difference between COX-1
and COX-2 is at position 523; here COX-1
has a bulky isoleucine whilst COX-2 has the
much smaller valine; which leaves a gap
which gives access to a side-pocket.8,11
This side-pocket is believed to be the
binding site for COX-2 inhibitors which in
general have a rigid side-extension which
can reach across the channel and interact
with the side-pocket.8,11  This aspect is the
basis of COX-2 inhibitor’s selectivity for
COX-2; they are in fact too bulky to fit into
the COX-1 channel.8,11
since October 2001), was voluntarily
withdrawn world-wide on 30th September,
2004.27,28 By the time it was withdrawn,
rofecoxib had been taken by an estimated
80 million people and sales had reached
US$2.5 billion in 2003.29
The rofecoxib withdrawal triggered a
debate regarding safety issues; in particular
the cardiovascular toxicity of other COX-2
inhibitors such as celecoxib, etoricoxib,
lumiracoxib, parecoxib and valdecoxib.  In
December, 2004 the Adenoma Prevention
with Celecoxib (APC) Study was stopped for
the same reasons as the APPROVe study:
patients on celecoxib (200mg twice daily or
400mg daily) had dose-dependently a 2.5
and 3.4 fold increased risk for
cardiovasacular events when compared to
placebo.30  8 April, 2005 saw the suspension
of sales and marketing of valdecoxib in
Europe and the US.31,32  This action followed
increasing concerns about the risk of serious
skin reactions, including Stevens-Johnson
Syndrome and toxic epidermal necrolysis, in
addition to established class-evidence of
cardiovascular risk, with the selective COX-2
inhibitors as well as evidence from two
randomised, placebo-controlled trials in
patients who had undergone a coronary-
artery bypass grafting which showed that
valdecoxib and its prodrug parecoxib
increased the risk of servious cardiovascular
events almost 3 fold.33-36
Several drug regulatory agencies
worldwide have undertaken a full review of
all selective COX-2-inhibitors.  The
Australian Therapeutics Goods
Administration (TGA), European Medicines
Agency (EMeA – of which both Medicines
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and Healthcare products Regulatory Agency
[MHRA] – UK and Medicines Authority
[MA] – Malta are parties to) and the New
Zealand Devices Safety Authority
(MEDSAFE) have all issued preliminary
accelerated reviews of the selective COX-2-
inhibitors, and pending a full review, have
all announced interim regulatory
restrictions on the use of these medicines.
Analysis by these agencies suggests a
class-effect with an increased risk of
cardio-vascular events for all COX-2
inhibitors which risk may increase with
dose and duration of exposure.37-42 As per
MHRA guidance this risk was considered
unlikely to exceed one extra serious
thrombotic event per 100 patient years,
over the rate for no treatment.39
Various reports concur with EMeA’s
decision that cardiovascular toxicity
represents a group effect of selective COX-
2-inhibitors.43,44  The very similar
cardiovascular toxicity can be explained by
their common mechanism of action.  Both
rofecoxib and celecoxib for example
suppress the formation of PGI
2
, which is
mostly produced by COX-2 in endothelium
and which inhibits platelet aggregation
causing vasodilation and prevents
proliferation of vascular smooth-muscle
cells.  These effects contrast sharply with
those of thromboxane (TxA
2
), the major
COX-1 product of platelets, which causes
platelet aggregation, vasoconstriction and
vascular proliferation.14 Selective COX-2-
inhibitors tend to cause a metabolic shift
towards TxA
2
 and consequently predispose
patients to thrombotic stroke and
myocardial infarction.14
Unexpectedly the Food and Drug
Administration (FDA) – USA came to a
different conclusion.  FDA declared that
despite the limitations of the available
data, overall, there is evidence, that
selective COX-2-inhibitors are associated
with an increased risk of serious adverse
cardiovascular (CV) events (e.g., MI,
stroke, and death). However FDA unlike
EMeA doubted that it is the presence of, or
the degree of, COX-2 selectivity that
accounts for these observations. In various
• Selective COX-2 inhibitors should not
be prescribed to patients with
cerebrovascular disease, established
ischaemic heart disease, or those with
moderate heart failure (NHYA class II-IV).
• For all patients, the balance of
gastrointestinal and cardiovascular risk
should be considered before prescribing
a COX-2 inhibitor, particularly for those
with risk factors for heart disease and
those taking low dose aspirin, for
whom gastrointestinal benefit has not
been conclusively demonstrated.
• The lowest effective dose of selective
COX-2 inhibitor should be used for the
shortest necessary period. Periodic re-
evaluation is recommended, especially
for osteoarthritis patients who may
only require intermittent treatment.
• Gastroprotective agents (such as H2-
receptor antagonists [e.g. ranitidine] or
proton-pump inhibitors [e.g.
omeprazole]) should be considered for
patients switched to non-selective
NSAIDs (i.e. traditional NSAIDs).
• Selective COX-2 inhibitors should not
be used routinely in the management
of patients with rheumatoid arthritis or
osteoarthritis.
Practice Points
• Selective COX-2 inhibitors should be
used in preference to standard NSAIDs
only when specifically indicated (i.e. for
patients with a history of
gastroduodenal ulcer or perforation or
gastrointestinal bleeding  or in patients
who are at a particularly high risk of
developing gastroduodenal ulcer,
perforation, or bleeding such as
patients aged over 65 years, patients
who are taking other medicines which
increase the risk of gastrointestinal
effects, patients who are debilitated or
those receiving long-term treatment
with maximal doses of standard NSAIDs)
and always after an assessment of
cardiovascular risk.
• MHRA Guidelines also indicate that
etoricoxib may be associated with more
frequent and severe effects on blood
pressure than some other COX-2
inhibitors and NSAIDs, particularly at
high doses. Etoricoxib treatment should
therefore not be initiated in patients
whose hypertension is not under
control.  Careful monitoring of blood
pressure is advised for patients taking
etoricoxib.
controlled clinical trials, COX-2 selective
drugs have been indistinguishable from
non-selective NSAIDs  (such as ibuprofen,
diclofenac and naproxen) in studies of
substantial size and duration.45  Further,
FDA declares that although on theoretical
grounds the addition of low-dose aspirin (a
COX-1 inhibitor) to a COX-2 selective drug
should resolve any increased cardiovascular
risk caused by COX-2 selectivity, this effect
has not in fact been observed in several
studies in which such comparisons are
possible. FDA declares that taken together,
these observations raise serious questions
about the so called “COX-2 hypothesis,”
which suggests that COX-2 selectivity
contributes to increased CV risk and that it
remains unclear to what extent the COX-2
selectivity of an individual drug predicts the
drug’s potential for an increased risk of
adverse CV events compared to drugs that
are less COX-2 selective. FDA declares that
an increased risk for serious (CV) adverse
events, represents a class effect of all
NSAIDs (excluding aspirin) and not just
selective COX-2 inhibitors.45,46
Conclusion
The selective COX-2-inhibitors situation
should spur us to be more conscious as
regards the importance of medicines
information and pharmacovigilance. The
continuous monitoring of the safe use of
medicinal products - one of the main
activities in pharmacovigilance - is critical
to the protection of public health. European
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legislation is in place to ensure that all
stakeholders including National Competent
Authorities (eg. MA-Malta), marketing
authorisation holders, applicants and
sponsors of clinical trials in the European
Economic Area (EEA) collect, collate and
exchange adverse drug reactions. This is
essential to ensure that rapid and
appropriate responses are made to potential
safety issues related to medicinal products.
The various regulatory restriction of the
COX-2 inhibitors go to show the extreme
importance of post-market surveillance
which include Phase 4 studies,
epidemiological studies as well as
spontaneous reporting by prescribers and
other healthcare professionals.
Underreporting of suspected ADRs by health
professionals is a major obstacle in drug
safety monitoring.  Locally this can be done
through the Medicines Authority, Malta. 48,49
It is already known that warnings and
letters to health care professionals have
little or no effect, so it would seem that
much more emphasis should be placed on
better communication strategies.50
Medicines Information Centers are essential
in providing useful, accurate and unbiased
information that can be accessed at an
appropriate place and time by everyone
with an interest in effective use of
medicines be it health-care professionals or
the patient.
Addendum
Following the submission of this review
two observational studies have been
published addressing the issue of
cardiovascular safety of COX-2 inhibitors
and NSAIDs.  A case-control study found a
similar risk of myocardial infarction for
celecoxib, rofecoxib, ibuprofen and
naproxen and a somewhat higher risk with
diclofenac; with the authors warranting a
reconsideration of the cardiovascualr safety
of all NSAIDs.51 A retrospective cohort study
in patients with congestive heart failure
found lower mortality in patients treated
with celecoxib than with rofecoxib and
traditional NSAIDs.52 These results should be
interpreted with caution. For example the
two studies contradict each other as regards
the similar risk of myocardial infarction for
naproxen and rofecoxib.  Both studies were
also criticised as regards quality of the
data.53
The Medicines Authority Malta, has
reassured patients and health-care
professionals regarding the safety of
ibuprofen but has advised prescribers and
patients alike that the lowest effective dose
of NSAIDs should be used for the shortest
period of time necessary for treatment.54
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